The original success of the copyright undeniably transformed the pharmaceutical landscape, but betting in companies primarily reliant on off-patent versions presents a complex picture. While early earnings were impressive, the end of patents and the emergence of cheaper alternatives have eroded sales. Consequently, a thorough assessment of current